FDA panel backs compounding of epitalon, rejects emideltide in narrow vote

The FDA advisory committee voted to allow compounding pharmacies to produce the peptide epitalon, while narrowly voting against allowing the production of emideltide.

The decision follows the panel’s earlier vote to permit compounding of four other peptides, moving the Make America Healthy Again movement, led by health secretary Robert F. Kennedy Jr., closer to broader access to these unapproved compounds.

The meetings highlighted a clash between the movement’s push for wider availability of peptides, which have gained popularity through social‑media endorsement, and scientists who warn about uncertain safety and efficacy.